山嵛酸钙 | 3578-72-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 山嵛酸钙
• CAS: 3578-72-1
• 化学式: C22H44CaO2
• 分子量: 380.7
• InChiKey: XOGZAYDJMKXLRK-UHFFFAOYSA-N

物化性质

• LogP：
  10.342 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  7.51
• 重原子数：
  25
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] REGIOSELECTIVE SYNTHESIS OF LETROZOLE<br/>[FR] SYNTHÈSE RÉGIOSÉLECTIVE DE LÉTROZOLE
  申请人：GENERICS UK LTD

  公开号：WO2010146391A1

  公开（公告）日：2010-12-23

  The present invention relates to an improved process for the preparation of letrozole (I) and its pharmaceutically acceptable salts, to compositions comprising letrozole or a pharmaceutically acceptable salt thereof, and to uses of such compositions. In particular it relates to a process and to novel intermediates for preparing letrozole and its salts substantially free from regioisomeric impurities.

  本发明涉及一种改进的来曲唑（I）及其药用可接受盐的制备方法，涉及包含来曲唑或其药用可接受盐的组成物，以及这些组成物的用途。特别是，它涉及一种几乎不含区域异构体杂质来曲唑及其盐的制备过程和新型中间体。
• [EN] ONE STEP PROCESS FOR THE PREPARATION OF CAPECITABINE<br/>[FR] PROCÉDÉ EN UNE ÉTAPE POUR LA PRÉPARATION DE LA CAPÉCITABINE
  申请人：GENERICS UK LTD

  公开号：WO2011104540A1

  公开（公告）日：2011-09-01

  The present invention relates a one step process for the preparation of capecitabine and analogues thereof, such as galocitabine, sapacitabine, 5'-deoxy-5-fiuoro-N- [(cyclohexyloxy)carbonyl]cytidine, and N-[(heptyloxy)carbonyl]cytarabine.

  本发明涉及一种用于制备卡培他滨及其类似物的一步法过程，例如盖洛他滨、沙帕他滨、5'-去氧-5-氟-N-[(环己氧基)羰基]胞苷和N-[(庚氧基)羰基]胞苷。
• [EN] CYCLIC SULPHINYL ESTERS OF CYTIDINE<br/>[FR] ESTERS SULFINYLE CYCLIQUES DE CYTIDINE
  申请人：GENERICS UK LTD

  公开号：WO2011067588A1

  公开（公告）日：2011-06-09

  The present invention relates to novel intermediates and to an improved process for the preparation of N- functionalised cytidine derivatives such as capecitabine, galocitabine and sapacitabine. Said intermediates are se from a copound of formula (A- 2), (A-3), (A-6), (A-7). wherein: R1 and R3 arc each independendy selected from hydrogen, -F, -CI, -Br, -I, -CN, -NO2, -N3, -O-R7, -S-R7, -N(R7)2, -N(R7)3+ or -0-Si(R7)3; R4 and R5 arc each independendy selected from hydrogen, -F, -CI, -Br and -I; R6 is selected from an alkyl, alkenyl, alkynyl, atyl, aiylalkyl, arylalkenyl, arylalkynyl, alkylaiyl, alkenylaryl or alkynylaryl group, each of which may optionally be substituted, and each of which may optionally include one or more heteroatoms N, O or S in its carbon skeleton; and each R7 is independendy selected from hydrogen, or an alkyl, alkenyl, alkynyl, atyl, aiylalkyl, arylalkenyl, arylalkynyl, alkylaiyl, alkenylaryl or alkynylaryl group, each of which may optionally he substituted, and each of which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, and wherein any two or more R7 groups may, together with rhe atom or atoms to which they are attached, form a cyclic alkyl, alkenyl, alkynyl, aryl, aiylalkyl, arylalkcnyl, arylalkynyl, alkylaiyl, alkenylaryl or alkynylaryl group, each of which may optionally be substituted, and each of which may optionally include one or more heteroatoms N, O or S in its carbon skeleton.

  本发明涉及新型中间体和改进的制备N-功能化胞嘧啶衍生物（如卡培他滨，加洛他滨和萨帕他滨）的过程。所述中间体是从化合物（A-2），（A-3），（A-6），（A-7）中选择的。其中：R1和R3各自独立地选自氢，-F，-CI，-Br，-I，-CN，-NO2，-N3，-O-R7，-S-R7，-N（R7）2，-N（R7）3+或-0-Si（R7）3; R4和R5各自独立地选自氢，-F，-CI，-Br和-I; R6选自烷基，烯烃基，炔基，芳基，取代的芳基烷基，取代的芳基烯烃基，取代的芳基炔基，烷基芳基，烯烃基芳基或炔基芳基基团，其中每个基团可以选择性地被取代，并且每个基团可以选择性地包含一个或多个N，O或S杂原子在其碳骨架中; 每个R7独立地选自氢，或烷基，烯烃基，炔基，芳基，取代的芳基烷基，取代的芳基烯烃基，取代的芳基炔基，烷基芳基，烯烃基芳基或炔基芳基基团，其中每个基团可以选择性地被取代，并且每个基团可以选择性地包含一个或多个N，O或S杂原子在其碳骨架中，任何两个或多个R7基团可以与它们附着的原子一起形成环烷基，烯烃基，炔基，芳基，取代的芳基烷基，取代的芳基烯烃基，取代的芳基炔基，烷基芳基，烯烃基芳基或炔基芳基基团，其中每个基团可以选择性地被取代，并且每个基团可以选择性地包含一个或多个N，O或S杂原子在其碳骨架中。
• LACTYLATE SYNTHESIS METHODS USING DILACTIDES
  申请人：Botts Jeff B.

  公开号：US20120065422A1

  公开（公告）日：2012-03-15

  The present invention involves a new synthesis route for the formation of lactylates. The method comprises reacting a dilactide with a compound comprising a hydroxy group. This reaction is preferably carried out in the presence of a cation or other source of alkalinity. Preferred compounds comprising a hydroxy group include any fatty acid and fatty acid alcohol (particularly C 1 -C 26 fatty acid chains). Preferred cations include cations of Group I and II metals, with sodium, calcium, and potassium cations being particularly preferred. The inventive reactions proceed much more rapidly than prior art lactylate synthesis reactions, and can be used to form 1-, 2-, 3-, 4-, and 5-lactylates.

  本发明涉及一种用于合成乳酰酸盐的新合成途径。该方法包括将二乳酸酯与含有羟基的化合物发生反应。该反应最好在存在阳离子或其他碱性来源的情况下进行。含有羟基的化合物包括任何脂肪酸和脂肪醇（尤其是碳链为C1-C26的脂肪酸链）。优选的阳离子包括I和II族金属的阳离子，其中特别优选的是钠、钙和钾阳离子。这种创新的反应比现有技术中的乳酰酸盐合成反应快得多，并可用于形成1-、2-、3-、4-和5-乳酰酸盐。
• Method for producing pharmaceutical dosage forms
  申请人：——

  公开号：US20030031720A1

  公开（公告）日：2003-02-13

  The invention relates to a method for producing a granulate while using spray-dried D-mannitol and to the production of pharmaceutical dosage forms comprised of granulates of this type. The invention additionally relates to granulates obtained by using this method and to pharmaceutical dosage forms, which contain statins, especially cerivastatin, and which can be produced from said granulates.

  该发明涉及一种利用喷雾干燥D-甘露醇制备颗粒的方法，以及由此类颗粒组成的制药剂量形式的生产。该发明还涉及通过使用该方法获得的颗粒，以及包含他汀类药物，特别是西立伐他汀，并可以从这些颗粒制备的制药剂量形式。